Two Sigma Investments LP Has $22.82 Million Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Two Sigma Investments LP increased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 12.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,243,442 shares of the biopharmaceutical company's stock after buying an additional 133,186 shares during the quarter. Two Sigma Investments LP owned 0.75% of ACADIA Pharmaceuticals worth $22,817,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 13,947,640 shares of the biopharmaceutical company's stock valued at $255,939,000 after buying an additional 104,444 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of ACADIA Pharmaceuticals by 27.0% during the fourth quarter. First Trust Advisors LP now owns 2,700,125 shares of the biopharmaceutical company's stock valued at $49,547,000 after buying an additional 574,251 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after buying an additional 1,966,607 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of ACADIA Pharmaceuticals during the fourth quarter valued at $40,935,000. Finally, Norges Bank purchased a new position in shares of ACADIA Pharmaceuticals during the fourth quarter valued at $25,555,000. Hedge funds and other institutional investors own 96.71% of the company's stock.

Insiders Place Their Bets

In related news, insider James Kihara sold 4,000 shares of the business's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $22.50, for a total transaction of $90,000.00. Following the completion of the transaction, the insider now owns 20,395 shares of the company's stock, valued at approximately $458,887.50. The trade was a 16.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the transaction, the director now directly owns 17,595 shares of the company's stock, valued at $320,756.85. This represents a 21.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,746 shares of company stock valued at $428,221 over the last quarter. Insiders own 26.50% of the company's stock.

ACADIA Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ:ACAD traded up $0.13 on Tuesday, reaching $22.11. The company had a trading volume of 374,498 shares, compared to its average volume of 2,363,219. ACADIA Pharmaceuticals Inc. has a twelve month low of $13.40 and a twelve month high of $25.23. The stock has a 50-day moving average price of $16.47 and a 200 day moving average price of $17.36. The stock has a market capitalization of $3.70 billion, a P/E ratio of 28.35 and a beta of 0.47.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The company had revenue of $244.32 million during the quarter, compared to analysts' expectations of $239.32 million. During the same quarter in the previous year, the firm earned $0.10 earnings per share. The business's quarterly revenue was up 18.7% compared to the same quarter last year. On average, sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ACAD has been the topic of a number of research analyst reports. Wall Street Zen upgraded ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. UBS Group lowered their target price on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Oppenheimer restated a "market perform" rating on shares of ACADIA Pharmaceuticals in a research note on Friday, May 16th. BMO Capital Markets boosted their target price on ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the company an "outperform" rating in a research note on Monday, May 19th. Finally, Morgan Stanley set a $24.00 target price on ACADIA Pharmaceuticals and gave the company an "equal weight" rating in a research note on Tuesday, May 20th. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.83.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.